Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
FEMALE
ID06842875

Effect of a Technology-based Collaborative Model on Persistent Hypertension and Preventive Care Attendance Among Postpartum People With Hypertensive Disorders of Pregnancy

Led by Women and Infants Hospital of Rhode Island · Updated on 2025-06-17

1536

Participants Needed

5

Research Sites

N/A

Total Duration

On this page

Sponsors

W

Women and Infants Hospital of Rhode Island

Lead Sponsor

B

Brown University

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research aims to evaluate a technology-based collaborative care model called RI-SPHERES among postpartum patients with hypertensive disorders of pregnancy (HDP). The trial will test whether RI-SPHERES is not worse than a standard self-measured blood pressure (SMBP) program in controlling persistent hypertension six weeks after delivery and improving preventive care attendance within one year. The study addresses challenges like low adherence to blood pressure checks due to barriers such as childcare and transportation, especially in racial or ethnic minority groups. Participants will be randomly assigned to one of two groups: the RI-SPHERES group or the standard SMBP program group. The RI-SPHERES group will use a LTE-enabled blood pressure cuff syncing to a smartphone app that sends automated reminders and adaptive messages based on blood pressure readings and symptoms, with a nurse practitioner-led collaborative care team supporting patients. The first six weeks focus on blood pressure control, then shift to preventive care support for up to one year. The standard SMBP group will manually enter blood pressure readings into an electronic record to be reviewed by clinical staff, with recommendations for monthly blood pressure checks and preventive care after six weeks postpartum. Participants will be involved for one year postpartum, during which blood pressure measurements, preventive care visits, and maternal health outcomes will be monitored. Assessments include short- and long-term blood pressure control, severe maternal morbidity, emergency visits, hospital readmissions, medication adjustments, and patient satisfaction. The study will also evaluate equity in care related to race, ethnicity, language, and geography. Data will be collected through the app, electronic medical records, and regular communications with the study team to track adherence and health outcomes.

CONDITIONS

Brief Title

Rhode Island - Statewide Postpartum Hypertension Remote Surveillance

Who Can Participate

Age: 18Years - 60Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Postpartum patient aged 18 years or more at any birthing hospital in Rhode Island
  • Diagnosed during pregnancy or after delivery with hypertensive disorder of pregnancy
  • Speaks English, Spanish, Portuguese, or Haitian-Creole
  • Owns a smartphone
Not Eligible

You will not qualify if you...

  • Prior enrollment in this trial
  • Prisoners or incarcerated people
  • Unable or unwilling to provide informed consent
  • Unable to communicate with study team, even with an interpreter

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or virtual)

Treatment

Duration - Up to 1 year postpartum

Participants engage in a self-measured blood pressure program. Those in the RI-SPHERES group use a Bluetooth-enabled blood pressure cuff synced to an app with automated reminders and adaptive messaging for the first six weeks postpartum. After six weeks, the focus shifts to preventive care with monthly engagement from a care manager to ensure primary care and specialist visits. Participants in the standard program manually report blood pressure readings and receive guidance to attend preventive care visits after six weeks.

Weekly or monthly virtual or in-person contacts depending on study group, including initial introduction and ongoing support

Follow-up

Duration - From six weeks postpartum until one year postpartum

Participants continue to be monitored for persistent hypertension and attendance of preventive care visits up to one year postpartum.

Monthly check-ins and preventive care visits as recommended

Trial Site Locations

Total: 5 locations

1

Newport Hospital

Newport, Rhode Island, United States, 02840

Not Yet Recruiting

2

Women & Infants Hospital of Rhode Island

Providence, Rhode Island, United States, 02903

Actively Recruiting

3

South County Hospital

Wakefield, Rhode Island, United States, 02879

Not Yet Recruiting

4

Kent Hospital

Warwick, Rhode Island, United States, 02886

Actively Recruiting

5

Landmark Hospital

Woonsocket, Rhode Island, United States, 02895

Actively Recruiting

Loading map...

Research Team

S

Stephanie Nunez, Research Coordinator

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Similar Trials

A Randomized, Placebo-controlled Trial of Dapagliflozin for ...

Gestational Hypertension

Actively Recruiting

1 location

Treatment of American Heart Association/American College of ...

Hypertension in Pregnancy

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Protocol for a type 1 hybrid effectiveness implementation trial to evaluate whether a technology-based collaborative care model is non-inferior to remote blood pressure monitoring on persistent hypertension and preventive care attendance among postpartum people with hypertension.

Stephanie D Nuñez, Lindsay M Spratt, Crystal F Ware...

https://pubmed.ncbi.nlm.nih.gov/41139061